Abstract:There is an acute unmet need to develop novel treatment regimens in the perioperative setting since many patients with muscle-invasive bladder cancer (MIBC) are not eligible for the current standard of care (SOC) neoadjuvant treatment with cisplatin-based chemotherapy. The introduction of immune checkpoint inhibitors (ICIs), both as monotherapy and in combination regimens with other ICIs, chemotherapy, or targeted drugs, may provide safe and clinically effective treatment options that could revolutionize current standard of care. In the neoadjuvant setting, compelling data from phase II clinical trials suggests that single-agent immunotherapy, as well as dual-checkpoint blockade, may emerge as reasonable alternatives to traditional cisplatin-based chemotherapy. Prospective studies combining ICIs with chemotherapy or with antibody-drug conjugates have also demonstrated robust outcomes. However, these studies are not yet practice changing and data from larger randomized studies are needed to confirm this benefit. In the adjuvant setting, nivolumab is the FDA-approved treatment based on a disease-free survival benefit relative to placebo in a randomized trial. However, it will be important to confirm an overall survival benefit of this treatment and to better identify patients who need additional adjuvant treatment based on novel biomarker data. The treatment of muscle-invasive bladder cancer is moving toward the individualization of treatment options based on specific tumor and patient characteristics and away from the one-size-fits-all approach that has dominated this space for the last couple of decades. Emerging biomarker data, such as with ctDNA, suggests that immunotherapy may confer greater benefit to selected patients. Identifying who those patients are will be of paramount importance since additional treatments always come with additional toxicities. On the other hand, the more favorable toxicity profiles of certain immunotherapy-based regimens may make them superior options for some patients who would otherwise be unable to tolerate other systemic regimens. In the near future, it is likely that subsets of patients with MIBC will be receiving treatments with predominantly immunotherapy-based regimens while many patients may still be treated with regimens containing a cisplatin-based chemotherapy backbone. Currently ongoing clinical trials will help to better define patient populations optimized for each treatment.

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology

Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges

Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions

Adjuvant Immunotherapy Improves Recurrence-Free and Overall Survival Following Surgical Resection for Intermediate/advanced Hepatocellular Carcinoma a Multicenter Propensity Matching Analysis

Immunoneoadjuvant Therapy with Immune Checkpoint Inhibitors of Gastric Cancer: an Emerging Exemplification

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing

Adjuvant immunotherapy for melanoma patients: progress and opportunities

A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review

Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies

Survival outcomes with adjuvant immunotherapy after hepatic resection in patients with intermediate/advanced (BCLC stage B/C) hepatocellular carcinoma: Insights from a propensity-matched multicenter study.

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Neoadjuvant Immunotherapy: A Promising New Standard of Care

Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer